In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma.

Abstract

Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.

• Authors: Bas D Koster, Tamarah D de Jong, Mari F C M van den Hout, Berbel J R Sluijter, Ronald J C L M Vuylsteke, Barbara G Molenkamp, Saskia Vosslamber, M Petrousjka van den Tol, Alfons J M van den Eertwegh, Tanja D de Gruijl
• Journal: Oncoimmunology (Oncoimmunology) Vol. 9 Issue 1 Pg. 1708066 ( 2020) ISSN: 2162-4011 [Print] United States
• PMID: 32002303 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC.

Chemical References

• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Dendritic Cells
• Female
• Granulocyte-Macrophage Colony-Stimulating Factor (therapeutic use)
• Humans
• Male
• Melanoma (drug therapy)
• Sex Factors